Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C19H20N2.C10H8O6S2 |
| Molecular Weight | 841.048 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)C1=CC=CC2=C(C=CC=C12)S(O)(=O)=O.CN3CCC4=C(C3)C5=CC=CC=C5N4CC6=CC=CC=C6.CN7CCC8=C(C7)C9=CC=CC=C9N8CC%10=CC=CC=C%10
InChI
InChIKey=CJUOSBUQOWKEKJ-UHFFFAOYSA-N
InChI=1S/2C19H20N2.C10H8O6S2/c2*1-20-12-11-19-17(14-20)16-9-5-6-10-18(16)21(19)13-15-7-3-2-4-8-15;11-17(12,13)9-5-1-3-7-8(9)4-2-6-10(7)18(14,15)16/h2*2-10H,11-14H2,1H3;1-6H,(H,11,12,13)(H,14,15,16)
Mebhydrolin (INN) or mebhydroline is a histamine H1-receptor antagonist. It is not available in the United States, but it is available in various other countries under the brand names Bexidal and Diazolin. It is used for symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allergic dermatosis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 Sources: http://www.rlsnet.ru/tn_index_id_1396.htm |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Bexidal Approved UseUnknown |
|||
| Primary | Bexidal Approved UseUnknown |
|||
| Primary | Bexidal Approved UseUnknown |
|||
| Primary | Bexidal Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: |
Disc. AE: Itching... AEs leading to discontinuation/dose reduction: Itching (8.3%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Itching | 8.3% Disc. AE |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
228-170-3
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | |||
|
100000086162
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | |||
|
6153-33-9
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | |||
|
22529
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | |||
|
CHEMBL1625607
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | |||
|
22822
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID3045566
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | |||
|
C025079
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | |||
|
O5G04RB25M
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | |||
|
m7109
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB03103MIG
Created by
admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD